The transition from preclinical to clinical obesity: the importance of a borderline stage
Clinical Science · 2026
DOI: 10.1042/cs20256728 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Science, 2026. Verfasst von Jesus E Maldonado-Arvizu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Bioquímica, Facultad de Medicina Mexicali, Universidad Autónoma de Baja California, Mexicali, Baja California, México. Hauptthemen laut MEDLINE: Obesity, Hypertriglyceridemia, Hyperinsulinism. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Obesity is a multifactorial health condition influenced by genetic predisposition and environmental factors, identified as a condition of persistent, mild systemic inflammation marked by an abnormal buildup of fat tissue, becoming clinical when accompanied by functional impairment of organs. This review explores the role of hyperinsulinemia and hypertriglyceridemia in driving the transition from a preclinical to a clinical state of obesity. Insulin resistance leads to compensatory hyperinsulinemia, impairing glucose homeostasis in skeletal muscle, liver, and adipose tissue. Concurrently, excessive dietary fat intake contributes to elevated triglyceride levels, which promote systemic inflammation and facilitate the onset of endocrine and cardio vascular disorders. Early risk factors, such as childhood obesity, as well as other contributors, including chronic psychological stress, alterations in gut microbiota, sleep disturbances, and vitamin D deficiency, are discussed in the context of their role in disease progression. Critically, the concept of a ‘borderline’ stage is introduced–a transitional phase characterized by elevated triglycerides, insulin resistance, and low-grade chronic inflammation–representing a critical point in the progression toward clinical obesity. Identifying this intermediary stage, even present in other pathologies, offers a valuable window for early interven tion, potentially preventing the establishment of chronic degenerative diseases associated with advanced obesity. Current strategies aimed at controlling hyperinsulinemia and hypertriglyceridemia, including dietary interventions, physical activity, and pharmacological approaches such as GLP-1 receptor agonists and SGLT2 inhibitors, should be considered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departamento de Bioquímica, Facultad de Medicina Mexicali, Universidad Autónoma de Baja California, Mexicali, Baja California, México.
- Laboratorio Multidisciplinario de Estudios Metabólicos y Cáncer, Facultad de Medicina Mexicali, Mexicali, Baja California, México.
- Centro de Investigación e Innovación en Salud (CIIS), Universidad Autónoma de Baja California, Mexicali, 21000, México.
- Centro de Ciencias de la Salud Mexicali, Universidad Autónoma de Baja California, Mexicali, 21000, México.
ORCID-Profile: Paula Vanessa Rios-Verdugo, José Fernando Díaz-Villanueva, Brenda Chimal-Vega, José L Vique-Sánchez, Victor García-González
Zitieren
APA
Maldonado-Arvizu, J. E., Rios-Verdugo, P. V., Díaz-Villanueva, J. F., Chimal-Vega, B., Vique-Sánchez, J. L., & García-González, V. (2026). The transition from preclinical to clinical obesity: the importance of a borderline stage. Clinical Science. https://doi.org/10.1042/cs20256728
Vancouver
Maldonado-Arvizu JE, Rios-Verdugo PV, Díaz-Villanueva JF, Chimal-Vega B, Vique-Sánchez JL, García-González V. The transition from preclinical to clinical obesity: the importance of a borderline stage. Clinical Science. 2026. doi:10.1042/cs20256728
BibTeX
@article{MaldonadoArvizu2026,
author = {Maldonado-Arvizu, Jesus E and Rios-Verdugo, Paula Vanessa and Díaz-Villanueva, José Fernando and Chimal-Vega, Brenda and Vique-Sánchez, José L and García-González, Victor},
title = {The transition from preclinical to clinical obesity: the importance of a borderline stage},
journal = {Clinical Science},
year = {2026},
doi = {10.1042/cs20256728}
}
EUVIMED